Treatment & Services
- Cardiac PET (Positron Emission Tomography) Study
- Cardiovascular Medicine Department
- Clinical Cardiology Section
- Clinical Trials
- Exercise and Cardiovascular Disease
- Nuclear Cardiology
Specialty in Diseases & Conditions
- Cardiovascular Disease
- Coronary Artery Disease
- Dilated Cardiomyopathy
- Heart Disease
- Heart Murmur
- Heart Valve Disease
- Heart Valve Infections
- High Cholesterol
- Hypertension - High Blood Pressure
Is Cleveland Clinic Part of Your Insurance?
Review a list of accepted insurance plans for our Northeast Ohio locations or learn more about purchasing a contracted managed care plan.View All Plans
Education & Professional Highlights
Education & Fellowships
Fellowship - University of Kentucky Chandler Medical Center
Lexington, KY USA
Residency - University of California Davis Medical Center
Sacramento, CA USA
Internship - University of California Davis Medical Center
Sacramento, CA USA
Medical School - University of Michigan Medical School
Ann Arbor, MI USA
Undergraduate - University of Michigan
Ann Arbor, MI USA
- Intensive Care Units Committee, University of Kentucky Medical Center, 1983-1992
- Aeromedical Patient Care for the University of Kentucky, 1987-1992
- Certification - Cardiovascular Medicine, American Board of Internal Medicine, 1983
- Certification - American Board of Internal Medicine, 1979
- Certification - National Board of Medical Examiners, 1979
- Principal Investigator, Global Cardiovascular Innovation Center, Cleveland Clinic, 2006
- Director, Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic
- Member, National Institutes of Health Level 1 Working Group on Clinical Trial Design National Heart, Lung, and Blood Institute (NHLBI), 2006
- National Government Service: Presently serves as Special Government Employee as periodic advisor to the U.S. Food and Drug Administration (FDA).
- Chairman, Cardiovascular Renal Drugs Advisory Committee, Department of Health and Human Resources, FDA, 2004 - 2005
- Member, Cardiovascular Renal Drugs Advisory Committee, Department of Health and Human Resources, FDA, 2000 - 2004
- Medical Director, Cleveland Clinic Cardiovascular Coordinating Center - an organization that directs multicenter clinical trials, 2001 - 2006
- Internal Medicine
- Internal Medicine - Cardiovascular Disease
General cardiology, heart disease, intravascular ultrasound, digital angiography and computer image processing, coronary intensive care
Awards & Honors
- Best Doctors, Cleveland Magazine, 2008, 2014
- America Top Doctors, Castle Connolly, 2014
- Golden Achievement for Medicine Award, Golden Age Centers of Greater Cleveland, 2012
- Simon Dack Award for Outstanding Scholarship, Awarded by Journal of American College of Cardiology Editorial Board and the American College of Cardiology, 2011
- Most Interesting People, Cleveland Magazine, 2010
- "100 Most Influential People in the World Scientists and Thinkers," TIME Magazine, 2007
- "Country 30 Most Powerful Forces in Business and Finance," Smart Money, 2007
- President, American College of Cardiology, a 34,000-member, non-profit, professional medical society whose mission is to advocate for quality cardiovascular care - through education, research promotion, development and application of standards and guidelines - and to influence health care policy, March 2006 thru March 2007
- Honorary Member of the Japanese College of Cardiology (JCC), 2007
- Award for Outstanding Contributions to Cardiovascular Research from the Gill Heart Institute of the University of Kentucky, 2004
- Outstanding Scientist Award, Cleveland Clinic, 2004
- Three-time recipient of the Outstanding Teacher Award, Fellows of Cardiovascular Medicine at Cleveland Clinic (2004, 1998, 1994)
- Dr. Nissen has received a number of additional honors and recognitions
Innovations & Patents
- Intravascular ultrasound (IVUS) and application to patients with atherosclerosis. Dr. Nissen has served as principal investigator for 6 major trials using IVUS to assess coronary disease and is currently conducting several additional atherosclerosis studies.
- Co-chairman, American College of Cardiology and the European Society of Cardiology International Writing Group to develop an Expert Consensus Document on Standards for the Acquisition, Measurement, and Reporting of Intravascular Ultrasound Studies, 1999-2001.
- Member, National Joint Committee of the American College of Cardiology and the American Heart Association to revise 1990 Coronary Angiography Guidelines, 1995-2000.
- Appointed committee member in the development of CD-ROM Version of the American College of Cardiology Self-Assessment Program (ACC-SAP), 1994-1996.
- Co-chairman, Joint Committees of the American College of Cardiology and National Electronics Manufacturers Association for Digital Imaging and Communication for Medicine (DICOM) Working Group I, Task Force to Develop Standards for Digital Image Archiving Devices for Cardiac Catheterization Laboratories, 1992-2000.
- American College of Cardiology
- Association of Professors of Cardiology
- American University of Physicians
- AHA Council on Cardiovascular Radiology (Elected Fellow 1991)
- AHA Council on Clinical Cardiology Recent National Committees and Positions2013 Harvard Multi-Regional Clinical Trial Center Working Group, Harvard University and Global Institute of Health, Cambridge, ME
- 2013 Writing Committee Cardiovascular Endpoints in Clinical Trials, American College of Cardiology
- 2010 - Present, Standardized Data Collection for Cardiovascular Trials, FDA
- 2010 Steering Committee Member, Clinical Trials Transformation Initiative (CTTI), Translational Institute, Duke University
- 2010 – Present, Editorial Board Seat, Prescribers Letter, Therapeutic Research Center
- 2010 Advisor, Prevention Magazine, Rodale Publishing
- 2002 – 2014 Senior Consulting Editor to the Journal of the American College of Cardiology
Research & Publications
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 5/24/2018, Dr. Nissen has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Consulting and/or Speaking. Dr. Nissen receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:
- Boehringer Ingelheim
Donation of Financial Interest. Dr. Nissen has consulted for, received compensation for serving as a fiduciary from, or received royalties from the following companies but instructed them to donate all compensation to not-for-profit causes or to the Cleveland Clinic to support research and education:
- Novo Nordisk, A/S
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.